Brucella recombinant multivalent epitope vaccine
By designing the multivalent epitope vaccine V_C4MEV, the immune response is activated by using specific brucella proteins, the problem of difficult prevention and control of brucella disease is solved, and strong immune protection is achieved.
Patent Information
- Application Number
- CN202410809453.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-21
- Publication Date
- 2024-11-26
AI Technical Summary
Brucellosis is difficult to cure and can easily lead to chronicity. The existing vaccine protection population coverage and immunogenicity are insufficient, making it difficult to effectively prevent and control the spread of the disease.
A recombinant multivalent epitope vaccine of Brucella V_C4MEV was designed, using IgV_CTLA-4, Omp19, Omp25, VirB9 and VirB10 proteins as target antigens, and a multivalent and multiepitope vaccine was formed through Linker linking to improve antigen presentation ability to activate the immune responses of CD8+T and CD4+T cells and B cells.
V_C4MEV vaccine can produce strong specific T-cell and B-cell-mediated immune responses, effectively block the infection of Brucella, has good immunogenicity and stability, and is suitable as a method to prevent brucellosis.
Smart Images

Figure CN119015404A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a recombinant multivalent epitope vaccine of Brucella. Background Art
[0002] Brucellosis, also known as Mediterranean remittent fever, is a zoonotic systemic infectious disease caused by Brucella. The three types of Brucella prevalent in China are mainly sheep (B. melitensis), cattle (B. bovis), and pigs (B. suis). Its clinical characteristics are long-term fever, sweating, joint pain, and hepatosplenomegaly. The chronic stage of the disease may cause damage to multiple organs and systems.
[0003] The complex pathogenic mechanism of Brucella makes the disease prone to chronicity, affecting all organs of the patient's body, and difficult to cure, which has seriously affected the economic development of Northwest China. Finding a vaccine with a wide protection group, high coverage, and strong immunogenicity is of great significance to maintaining national security, promoting the sustainable development of the aquaculture industry, ensuring food safety and environmental safety, protecting people's health, and maintaining social stability. Summary of the invention
[0004] The purpose of the present invention is to provide a Brucella recombinant multivalent epitope vaccine to solve the above technical problems.
[0005] One of the purposes of the present invention is to provide: a Brucella recombinant multivalent epitope vaccine, comprising IgV_CTLA-4, linked CD8 + T cell epitopes, ligated CD4 + T cell epitope, linear B cell epitope after ligation and conformational B cell epitope after ligation; the amino acid sequence of IgV_CTLA-4 protein is SEQ ID NO: 15; the CD8 + The amino acid sequence of the T cell epitope is: SEQ ID NO: 59; the ligated CD4 + The amino acid sequence of the T cell epitope is SEQ ID NO: 60; the amino acid sequence of the linear B cell epitope after ligation is SEQ ID NO: 61; the amino acid sequence of the conformational B cell epitope after ligation is SEQ ID NO: 62;
[0006] Preferably, it also includes a PADRE sequence and a 6xHis sequence.
[0007] Preferably, Linker-EAAK, Linker-AAY, Linker-GPGPG and Linker-KK are also included.
[0008] Preferably, the amino acid sequence of the Brucella recombinant multivalent epitope vaccine is SEQ ID NO:63.
[0009] The second object of the invention is to provide a method for preparing the above-mentioned recombinant multivalent epitope vaccine, characterized in that it comprises the following steps:
[0010] Step 1: CD8 + T cell epitopes were connected by Linker-AAY to obtain linked CD8 + T cell epitope, amino acid sequence: SEQ ID NO: 59; CD4 + T cell epitopes were connected by Linker-GPGPG to obtain linked CD4 + T cell epitope, the amino acid sequence is: SEQ ID NO: 60; the linear B cell epitope is connected by Linker-KK to obtain a connected B cell epitope, the amino acid sequence is: SEQ ID NO: 61; the conformational B cell epitope is connected by Linker-KK to obtain a connected conformational B cell epitope, the amino acid sequence is: SEQ ID NO: 62;
[0011] In the second step, IgV_CTLA-4, PADRE sequence, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62 and 6xHis sequence were connected in order. The amino acid sequence of IgV_CTLA-4 is SEQ ID NO:15; SEQ ID NO:15, PADRE sequence and SEQ ID NO:59 were connected in sequence through Linker-EAAK; SEQ ID NO:59 and SEQ ID NO:60 were connected through Linker-GPGPG; SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62 and 6xHis sequence were connected through Linker-KK to obtain the recombinant multivalent epitope vaccine V_C4MEV with an amino acid sequence of SEQ ID NO:63.
[0012] The third object of the invention is to provide the use of the above-mentioned recombinant multivalent epitope vaccine in stimulating the body to resist Brucella.
[0013] A fourth object of the invention is to provide a vector for the nucleic acid of the above-mentioned recombinant multivalent epitope vaccine.
[0014] The fifth object of the invention is to provide the use of the above-mentioned recombinant multivalent epitope vaccine in the preparation of drugs for preventing and treating brucellosis.
[0015] The beneficial effects of the present invention are:
[0016] 1. In the context of increasing cases of Brucella infection year by year, the present invention uses immunoinformatics technology, based on the important invasive role of outer membrane protein 19 (Omp19) and outer membrane protein 25 (Omp25) of Brucella melitensi in Brucella infection, VirB9 and VirB10 proteins in the type IV secretory system (T4SS) assist Brucella to avoid lysosomal decomposition, and the precise targeting effect of IgV_CTLA-4, with Omp19, Omp25, VirB9 and VirB10 proteins as target antigens, and based on human HLA-Ⅰ and HLA-Ⅱ high-frequency restriction alleles to predict CD8 + T and CD4 + T cell epitopes, and linear and conformational B cell epitopes were predicted; IgV_CTLA-4 was used as the targeting molecule to improve the antigen presenting ability of antigen presenting cells (APCs) to vaccine proteins, and a multivalent, multi-epitope recombinant vaccine with these four proteins as target antigens was designed and developed, and named "V_C4MEV". V_C4MEV has strong immunogenicity and can produce strong specific T cell responses and B cell-mediated immune responses, which can stimulate the body to produce immune responses against Brucella.melitensi infection and block the transmission between livestock and humans.
[0017] 2. The V_C4MEV provided by the present invention consists of 890 amino acids, has a molecular weight of 92,319.28KD, and a molecular formula of C 4052 H 6409 N 1185 O 1233 S 27 The protein is stable, hydrophilic and soluble, non-allergenic, and has good immunogenicity. It may be a powerful method to prevent the occurrence and development of brucellosis in the future. It is expected to activate the body to produce an effective immune response against Brucella infection, block the transmission between livestock and humans, and achieve effective prevention and control of human brucellosis.
[0018] 3. By injecting mice with V_C4MEV vaccine protein, an in vivo experimental model was established, confirming that V_C4MEV can activate the specific cellular immunity of mice. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1Analysis of the physical and chemical properties of proteins; A: Prediction of protein antigenicity; B: Prediction of the theoretical pI of proteins; C: Prediction of the instability index of proteins; D: Prediction of the grand average of hydropathicity (GRAVY) of proteins;
[0020] Figure 2 Prediction of signal peptide and transmembrane region of protein; A: VirB9 signal peptide predicted by SignalP-5.0; B: VirB9 signal peptide predicted by LiPOP1.0; purple represents transmembrane region, blue represents intracellular region, and yellow represents extracellular region; C: Omp19 signal peptide predicted by SignalP-5.0; D: Omp19 signal peptide predicted by LiPOP1.0; E: Omp25 signal peptide predicted by SignalP-5.0; F: Omp25 signal peptide predicted by LiPOP1.0; G: VirB10 signal peptide predicted by SignalP-5.0; H: TMHMM-2.0 analysis of transmembrane region of CTLA-4; purple represents transmembrane region, blue represents intracellular region, and yellow represents extracellular region;
[0021] Figure 3 CBEs of antigens; A: ElliPro predicted CBEs residues of VirB9: L6, L7, A8, C9, I10, L11, I12, T13, L14, A15, S16, P17, S18, W19, A20; B: ElliPro predicted CBEs residues of VirB10: K139, S140, S141, G142, D143, T144, V145, V146, Q147;
[0022] Figure 4 Schematic diagram of the vaccine construction; A: Schematic diagram of the construction of MEV; PADRE sequence (orange), CTLEs (pink), HTLEs (blue), LBEs (yellow), CBEs (cyan) and polyhistidine tag (purple); (B) Schematic diagram of the construction of V_C4MEV; CTLA-4 extracellular domain (light green), PADRE sequence (orange), CTLEs (pink), HTLEs (blue), LBEs (yellow), CBEs (cyan) and polyhistidine tag (purple);
[0023] Figure 5 Prediction of the secondary and tertiary structures of V_C4MEV; A: Prediction of the secondary structure of V_C4MEV; B: Prediction of the tertiary structure of V_C4MEV; (C) Hydrogen bonds of V_C4MEV, the "pink area" represents the donor, and the "green area" represents the acceptor;
[0024] Figure 6Evaluation of the tertiary structure model of V_C4MEV; A: red represents α-helix, green represents β-turn, cyan represents β-sheet, and gray represents random coil; B: Z-score diagram of the tertiary structure of V_C4MEV; C: Ramachandran diagram;
[0025] Figure 7 The docking of V_C4MEV molecule and B7 molecule; blue represents V_C4MEV molecule, and green represents B7-1 and B7-2;
[0026] Figure 8 Results of immune simulation; A: B cell isotypes in different states; B: immunoglobulins in various states; C: Th cell isotypes in different states; D: TC cell isotypes in different states; E: NK cells in different states; F: DC groups in various states; G: macrophages in various states; H: states of different subsets of Th cells; I: interleukins and cytokines in various states;
[0027] Figure 9 A: is the expression plasmid map of the antigen protein; A: is the plasmid map of the MEV protein; B: is the plasmid map of V_C4HBL.
[0028] Figure 10 The results of in vitro experiments; A: Flow gating strategy for detecting IFN-γ and IL-4 by CBA method; B: The figure shows the statistical evaluation of IFN-γ and IL-4 concentration levels in the control group, M group and V group. Each group consists of 6 samples (n=6), and two independent sample t-tests were used for statistical analysis (**P<0.01, ***P<0.001); C: ELISPOT spots are shown, and purple spots represent ASCs; D: The statistical analysis in the chart uses two independent sample t-tests (*P<0.05) to compare the ASC spot counts between the M group and the V group.
[0029] Figure 11 Results of in vivo experiments; A: Flowchart illustrating the mouse vaccination strategy. Different groups of mice were injected with "adjuvant", "adjuvant + M protein" or "adjuvant + V_C4MEV protein"; B: CD4 + Flow gating strategy for T cells and CD8+ T cells; C: Statistical analysis in the graphs used two independent sample t-tests (*, *, *, **) to compare CD4 + The percentages of T cells and CD8+T cells; D: shows the statistical evaluation of IFN-γ and IL-4 concentration levels in the control group, M group, and V group. Statistical analysis was performed using two independent sample t tests (**, ***); E: shows the statistical analysis of total IgG concentration levels in the control group, M group, and V group. The statistical method was two independent sample t tests (***). DETAILED DESCRIPTION
[0030] The following is further described in detail through specific implementation methods:
[0031] 1. Vaccine design candidate antigens
[0032] In this experiment, Brucella melitensi protein was used as the target antigen, and the amino acid sequences of type IV secretory system (T4SS) components (VirB1-VirB11), outer membrane protein 19 (Omp19), outer membrane protein 25 (Omp25) and CTLA-4 protein were obtained from the National Center for Biotechnology Information (NCBI) database.
[0033] The amino acid sequence of Omp19 protein is (SEQ ID NO: 1):
[0034] MGISKASLLSLAAAGIVLAGCQSSRLGNLDNVSPPPPPPAPVNAVPAGTVQKGNLDSPTQ FPNAPSTDMSAQSGTQVASLPPASAPDLTPGAVAGVWNASLGGQSCKIATPQTKYGQGYRAG PLRCPGELANLASWAVNGKQLVLYDANGGTVASLYSSGQGRFDGQTTGGQAVTLSR.
[0035] The amino acid sequence of Omp25 is (SEQ ID NO: 2):
[0036] MRTLKSLVIVSAALLPFSATAFAADAIQEQPPVPAPVEVAPQYSWAGGYTGLYLGYGWNKAKTSTVGSIKPDDWKAGAFAGWNFQQDQIVYGVEGDAGYSWAKKSKDGLEVKQGFEGSLRARVGYDLNPVMPYLTAGIAGSQIKLNNGLDDESKFRVGWTAGAGLEAKLTDNILGRVEY RYTQYGNKNYDLAGTTVRNKLDTQDFRVGIGYKF.
[0037] The amino acid sequence of VirB1 protein is (SEQ ID NO: 3):
[0038] MVPFLVLAQQCAPTVAPQTMAAIVQVESGFNPYAIGVVGGRLVRQPVSLDEAITTAQSLEAKGWNFSLGIAQVNRYNLPKYGSTYAQAFDPCKNLKMGSKILEDCYRRAIVKMPGQEQG ALRAAFSCYYAGNFTGGFKTKPGSPSYVQKVVASADVTTKPIVVVPMIRKTPDAAAAVAAPVKKRQPADRNSVLVDLHPSSQSMPATGAANAPVRLKTEQPATTDAPPGKDNTDGVVVF.
[0039] The amino acid sequence of VirB2 protein is (SEQ ID NO: 4):
[0040] MKTASPSKKSLSRILPHLLLALIVSIAAIEPNLAHANGGLDKVNTSMQKVLDLLSGVSITI VTIAIIWSGYKMAFRHARFMDVVPVLGGALVVGAAAEIASYLLR.
[0041] The amino acid sequence of VirB3 protein is (SEQ ID NO:5):
[0042] MTTAPQESNARSAGYRGDPIFKGCTRPAMLFGVPVIPLVIVGGSIVLLSVWISMFILPLIV PIVLVMRQITQTDDQMFRLLGLKAQFRLIHFNRTGRFWRASAYSPIAFTKRKRES.
[0043] The amino acid sequence of VirB4 protein is (SEQ ID NO:6):
[0044] MGAQSKYAQQLNNERSLAPFIPFRSQVGPTTVITRDGDFVRTWRIAGLAFETQDKEKLLIRKDQLNTLFRAIASNNVALWSHNVRRRTWDHLKSFFSNPFCDALDKKYYGSFSGYRMMSNELYLTVIYRPVPAKISRLFNVAVHRSHAEILQEQKLAIRKLDEIGNQIETSLRRYGGDDGRGIEVLSTYEDKHGALCSQQLEFYNFLLSGEWQKVRVPSCPLDEYLGTGWVYAGTETIEIRTASATRYARGIDFKDYANHTEPGILNGLMYSDYEYVITQSFSFMTKRDGKEFLTRQKQRLQNTEDGSASQIMEMDIAIDQLGRGDFVMGEYHYSLLVFAEDMETVRHNTSHAMNILQDNGFLATVIATATDAAFYAQLPCNWRYRPRVAGLTSLNFAGLSCFHNFRAGKRDGNPWGQALTLLKTPSGQPAYLNFHYSKGDEDNFDKKLLGNTRIIGQSGAGKTVLMNFCLAQAQKYLHNAPMGMCNVFFDKDQGAKGTILAIGGKYLAIRNGEPTGFNPFQMEPTAGNILFLEKLVQVLVSRDGQHVTTTDESRISHAIRTVMRMRPELRRLSTVLQNVTEGSDRQDRENSVAKRLAKWCFDDGTGKRGTFWWVLDCPQDQIDFNTHSNYGFDGTDFLDNADVRTPISMYLLHRMELAIDGRRFIYWMDEAWKWVDDEAFSEFANNKQLTIRKQNGLGVFATQMPSSLLNSKVASALVQQVATEIYLPNPKADYHEYTDGFKVTNEEFDIIRSMSEESRMFLVKQGHHSMICRLELNGFDDELAILSGSSDNNELLDQVIAEVGDDPSVWLPVFQERRKARIASSKSTGR。
[0045] The amino acid sequence of VirB5 protein is (SEQ ID NO:7):
[0046] MKKIILSFAFALTVTSTAHAQLPVTDAGSIAQNLANHLEQMVKFAQQIEQLKQQFEQQKMQFDALTGNRGLGDILRDPTLRSYLPHNWRDLYEAVMSGGYLAAAGETANLLRKSQVYDP CASISDKDQRIACEAKVVKPVQDKVMTSKAYDATDKRLQEIESLMQEINKTGDPKAIAELQGRIESENAMIQNEDTRLHLYQQMAEAQDKLLDERQHELDAKDNARRGYPQPKALEAAY。
[0047] The amino acid sequence of VirB6 protein is (SEQ ID NO:8):
[0048] MVNPVIFEFIGTSIHNQLNNYVTMVASNTMNMIATTAVLAGGLYYTAMGILMSVGRIEGPFSQLVISCIKFMLIAAFALNISTYSEWVIDTVHNMESGFADAFAGNHGTPSSTIYQTLDNSLGKGWNIAAMLFEKGDNRGLTQIVQGFSELLLSFLVAGSTLILAGPTGAMIVATNAVIAILLGIGPLFILALGWAPTRGFFDRWFGTIVTSILQVALLSAVLSISSAIFSRMVAAINLASATQSTLFSCLSLTAVTIVMPYMMYKVYEYGGILGSSISAATISLGSLAVNTAKSGGGAMTSIFSGSSGGGGSGSAKAGGESSYSAGGNAMWSPAFRQHVLGQFNRD。
[0049] The amino acid sequence of VirB7 protein is (SEQ ID NO:9):
[0050] MKKVILAFVATAFLAGCTTTGPAVVPVLDGKPRVPVNKSVPAKPPLAQPNPVDTYED。
[0051] The amino acid sequence of VirB8 protein is (SEQ ID NO:10):
[0052] MFGRKQSPQKSVKNGQGNAPSVYDEALNWEAAHVRLVEKSERRAWKIAGAFGTITVLLGIGIAGMLPLKQHVPYLVRVNAQTGAPDILTSLDEKSVSYDTVMDKYWLSQYVIARETYDWYTLQKDYETVGMLSSPSEGQSYASQFQGDKALDKQYGSNVRTSVTIVSIVPNGKGIGTVRFAKTTKRTNETGDGETTHWIATIGYQYVNPSLMSESARLTNPLGFNVTSYRVDPEMGVVQ。
[0053] The amino acid sequence of VirB9 protein is (SEQ ID NO:11):
[0054] MKRIFLLACILITLASPSWATKIPSGSKYDSRIQYVDYNSGDVVLVRALPGVGARIVFAPGENIEDVASGFTQGWEFKASHNILYLKARSMTLSHSNQSIDMAPEPGKWDTNLMVTTDQRMYDFDLRLMPGRNNQRVAYRVQFRYPAAAAAAAVAAAQKRVVQARMNARPSPVNWNYTMQVGTNSASIAPTLAYDDGRFTYLRFPNNRDFPAAFLVAEDKSESIVNSHIDPSAPDILVLHRVAKQMVLRLGNKVIGIYNESFNPDGVPARDGTTVPRVKRVIKSPGENLQ。
[0055] The amino acid sequence of VirB10 is (SEQ ID NO:12):
[0056] MTQENIPVQPGTLDGERGLPTVNENGSGRTRKVLLFLFVVGFIVVLLLLLVFHMRGNAENNPHSYKTMVQTSTVPMRTFKLPPPPPPAPPEPPAPPPAPAMPIAEPAAAALSLPPLPDDTPAKDDVLDKSASALMVVTKSSGDTVVQTTNARIQALLDSQKNTKQDAGSLGTLLHGTQTDARMASLLRNRDFLLAKGSIINCALQTRLDSTVPGMAACVVTRNMYSDNGKVLLIERGSTISGEYDANVKQGMARIYVLWTRVKTPNGVVIDLDSPGADPLGGAGLPGYIDSHFWKRFGGALMLSTIETLGRYATQKVGGGGSNQINLNTGGGESTSNLASTALKDTINIPPTLYKNQGEEIGIYIARDLDFSSVYDVKPK。
[0057] The amino acid sequence of VirB11 is (SEQ ID NO:13):
[0058] MMSNRSDFIVPDEAAVKRAASVNFHLEPLRPWLDDPQITEVCVNRPGEVFCERASAWEYYAVPNLDYEHLISLGTATARFVDQDISDSRPVLSAILPMGERIQIVRPPACEHGTISVTIRKPSFTRRTLEDYAQQGFFKHVRPMSKSLTPFEQELLALKEAGDYMSFLRRAVQLERVIVVAGETGSGKTTLMKALMQEIPFDQRLITIEDVPELFLPDHPNHVHLFYPSEAKEEENAPVTAATLLRSCLRMKPTRILLAELRGGETYDFINVAASGHGGSITSCHAGSCELTFERLALMVLQNRQGRQLPYEIIRRLLYLVVDVVVHVHNGVHDGTGRHISEVWYDPNTKRALSLQHSEKAQ。
[0059] The amino acid sequence of CTLA-4 protein is (SEQ ID NO:14):
[0060] MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQV NLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFLLTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN.
[0061] The amino acid sequence of IgV_CTLA-4 protein is (SEQ ID NO: 15):
[0062] HVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTF LDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVI.
[0063] The online tools protparam, Vaxijen, and AllergenFPv.1.0 were used to analyze the physical and chemical properties of proteins, theoretical pI ( Figure 1 ), antigenicity ( Figure 1 ), allergic (Table 1).
[0064] Table 1: Allergenicity of various proteins
[0065]
[0066]
[0067] Based on the principles of non-sensitization, high antigenicity and hydrophilicity, the present invention selected Omp19, Omp25, VirB9 and VirB10 as candidate proteins for vaccine design.
[0068] 2. Prediction of protein transmembrane domains and signal peptides
[0069] The signal peptides of the four proteins were predicted by the online prediction server SignalP-5.0 and then removed.
[0070] SignalP-5.0 and LiPOP1.0 were used to predict the VirB9 signal peptide, such as Figure 2 A and Figure 2As shown in B, purple represents the transmembrane region, blue represents the intracellular region, and yellow represents the extracellular region. SignalP-5.0 predicts that the signal peptide of VirB9 spans 1-21 amino acids, while LiPOP1.0 predicts that it spans 15-26 amino acids. Therefore, it can be considered that the signal peptide of VirB9 is 1-26 amino acids.
[0071] SignalP-5.0 and LiPOP1.0 were used to predict the Omp19 signal peptide, such as Figure 2 C and Figure 2 As shown in D, SignalP-5.0 and LIPOP1.0 predicted that the signal peptide of Omp19 was 1-21 and 17-31, respectively, that is, the signal peptide of Omp19 was 1-31.
[0072] SignalP-5.0 and LiPOP1.0 were used to predict the Omp25 signal peptide, such as Figure 2 E and Figure 2 As shown in Figure F, the signal peptide of Omp25 was predicted to be 1-24 and 16-30 amino acids using SignalP-5.0 and LIPOP1.0, respectively. Therefore, the signal peptide of Omp25 may span 1-30 amino acids.
[0073] The ID name of VirB10 in the Uniprot / NCBI database is VIBRA. SignalP-5.0 and LiPOP1.0 were used to predict the signal peptide of VirB10, such as Figure 2 As shown in G, VirB10 does not contain a signal peptide.
[0074] The IgV_CTLA-4 sequence in the CTLA-4 amino acid sequence was selected for vaccine design, and the online software TMHMM-2.0 was used to predict the transmembrane region sequence of CTLA-4 to verify the rationality of the IgV_CTLA-4 sequence, that is, to check whether the IgV_CTLA-4 sequence is the extracellular region of the CTLA-4 protein. The experimental results are as follows Figure 2 As shown in FIG. 3 , the extracellular region of the CTLA-4 protein is predicted to be from amino acids 43 to 161 using the online software TMHMM-2.0, which is consistent with the entire sequence of IgV_CTLA-4 covering amino acids 38 to 152.
[0075] 3. Prediction of antigenic epitopes
[0076] The online servers IEDB and NetCTLpan-4.0 were used to predict the helper T lymphocyte epitopes (HTLEs) and cytotoxic T lymphocyte epitopes (CTLEs) of Omp19, Omp25, VirB9 and VirB10, and HLA-A*1101 (13.46%), HLA-A*0201 (12.50%), HLA-A*0301 (10.10%), HLA-DRB1*0701 (16.35%), HLA-DRB1*1501 (8.65%) and HLA-DRB1*0301 (7.69%) were selected as prediction objects. Linear B lymphocyte epitopes (LBEs) and conformational B cell epitopes (CBEs) were predicted using ABCpred and IEDB servers.
[0077] In this experiment, the number of HLA-Ⅰ and HLA-Ⅱ alleles was increased when predicting T cell epitopes. + T cell epitopes, CD4 in HLA class II alleles + T cell epitopes and B cell epitopes were selected, and the stability of the selected epitopes was verified. These high-frequency antigen epitopes screened can increase the coverage of vaccines for different ethnic groups around the world and expand the vaccine's protection population.
[0078] As shown in the results of Tables 2 , 3 and 4 , CTLEs and HTLEs with antigenicity > 0.9, non-toxicity and non-sensitizing properties were screened out from the top ten epitopes, and epitopes with antigenicity > 0.9, non-toxicity and non-sensitizing properties were screened out from the top ten LBEs with scores > 0.8 for vaccine construction.
[0079] Finally there are 10 CTLEs, 21 HTLEs, 10 LBEs and 2 CBEs. Figure 3 There are two CBEs of the antigen; A: ElliPro predicted CBEs residues of VirB9: L6, L7, A8, C9, I10, L11, I12, T13, L14, A15, S16, P17, S18, W19, A20; B: ElliPro predicted CBEs residues of VirB10: K139, S140, S141, G142, D143, T144, V145, V146, Q147.
[0080] The screened CTLEs, HTLEs, CBEs and LBEs were non-toxic and non-sensitizing.
[0081] Table 2: Final selected CTLEs and HTLEs
[0082]
[0083]
[0084]
[0085] Note: HLA-DRB1*07:01 represents an allele, which is also an MHC-II class molecule and is predicted to be CD4 + T cell epitopes. The same allele can predict multiple epitopes. This writing is in its fixed format, refer to the literature (Design of a multi-epitope vaccine candidate against Brucella melitensis); The same allele can predict multiple epitopes.
[0086] Table 3: Final selected LBEs (ABCpred)
[0087]
[0088] Table 4: Final selected conformational B cell epitopes (ElliPro)
[0089] Protein start end SEQ ID NO: peptide Score Antigenicity VirB9 6 20 SEQ ID NO:57 LLACILITLASPSWA 0.857 0.8793 VirB10 139 147 SEQ ID NO:58 KSSGDTVVQ 0.949 1.5139
[0090] 4. Construction of vaccine protein
[0091] The high-frequency antigen epitopes obtained by screening are connected using a linker. When connecting, attention is paid to the adaptability and specificity of the linker selection.
[0092] (1) Replace CD8 in Table 2 + T cell epitopes are connected by Linker-AAY, and the connected CD8 + The amino acid sequence of the T cell epitope is (SEQ ID NO: 59):
[0093] SASIAPTLAY AAY RLMPGRNNQR AAY ASLYSSGQGR AAY ASLGGQSCK AAY TGGQAVT LSR AAY VLYDANGGTV AAY SAPDLTPGAV AAY SLYSSGQGR AAY TAGIAGSQIK AAY RVGW TAGAGL.
[0094] (2) Replace the CD4 in Table 2 + T cell epitopes are linked via Linker-GPGPG, and the linked CD4 +The amino acid sequence of the T cell epitope is (SEQ ID NO: 60):
[0095] GVGARIVFAPGENIE GPGPG QGWEFKASHNILYLK GPGPG TQGWEFKASHNILYL GPGPG SGDVVLVRALPGVGA GPGPG NLMVTTDQRMYDFDL GPGPG SGDTVVQTTNARIQA GPGPG GDTVVQTTNARIQAL GPGPG SSGDTVVQTTNARIQ GPGPG ETLGRYATQKVGGGG GPGPG TPNGVVIDLDSPGAD GPGPG KTPNGVVIDLDSPGA GPGPG VNGKQLVLYDANGGT GPGPG QLVLYDANGGTVASL GPGPG KFRVGWTAGAGLEAK GPGPG SKFRVGWTAGAGLEA G PGPG ESKFRVGWTAGAGLE GPGPG FRVGWTAGAGLEAKL GPGPG EGSLRARVGYDLNPV GPGPG FEGSLRARVGYDLNP GPGPG LRARVGYDLNPVMPY GPGPG SLRARVGYDLNPVMP.
[0096] (3) The B cell epitopes in Table 3 were linked by Linker-KK. The amino acid sequence of the linear B cell epitope after linking is (SEQ ID NO: 61):
[0097] PSPVNWNYTMQVGTNS KK ERGSTISGEYDANVKQ KK HGTQTDARMASLLRNRKKLGRYATQKVGGGGSNQ KK IATPQTKYGQGYRAGP KK PMPRMETERMEMRANE KK MRMEKDATERMEMRAN KK AGIAGSQIKLNNGLDD KK RVEYRYTQYGNKNYDLKK NGENICPRTEINSRCE.
[0098] (4) The conformational B cell epitopes in Table 4 were linked by Linker-KK. The amino acid sequence of the linked conformational B cell epitope was (SEQ ID NO: 62):
[0099] LLACILITLASPSWA KK KSSGDTVVQ.
[0100] (5) The high-frequency antigen epitopes screened were then purified using linker protein according to the sequence of IgV_CTLA-4 (SEQ ID NO: 15), PADRE, and CD8 + T cell epitope (SEQ ID NO: 59), ligated CD4 + The sequence of the ligated T cell epitope (SEQ ID NO: 60), the ligated linear B cell epitope (SEQ ID NO: 61), the ligated conformational B cell epitope (SEQ ID NO: 62) and the 6xHis sequence (HHHHHH).
[0101] When connected, IgV_CTLA-4 (SEQ ID NO: 15), PADRE sequence and CD8 + T cell epitope (SEQ ID NO: 59) is sequentially linked via Linker-EAAK; the linked CD8 + T cell epitope (SEQ ID NO: 59) and ligated CD4 + T cell epitope (SEQ ID NO: 60) was linked via Linker-GPGPG; the linked CD4 + The T cell epitope (SEQ ID NO: 60), the linked linear B cell epitope (SEQ ID NO: 61), the linked conformational B cell epitope (SEQ ID NO: 62) and the 6xHis sequence (HHHHHH) were linked by Linker-KK.
[0102] When connecting the above-mentioned high-frequency epitopes, attention is paid to the adaptability and specificity of linker selection. At the same time, the use of these dominant antigenic epitopes and the optimized design of linker proteins can enhance the immunogenicity of vaccine proteins.
[0103] Brucella Omp19, Omp25, VirB9 and VirB10 proteins were used as target antigens, IgV_CTLA-4 was used as adjuvant, Linker-EAAK was used to connect IgV_CTLA-4 and PADRE sequence (AKFVAAWTLKAAA), and Linker-AAY was used to connect CD8+ T cell epitope, linked to CD4 using Linker-GPGPG + T cell epitope, Linker-KK connects B cell epitope and 6xHis sequence (polyhistidine tag, added at C-terminus, HHHHHH). ProtParam, VaxiJen, SolPro and AllergenFP tools were used to predict the physicochemical properties, antigenicity, solubility and allergenicity of vaccine proteins.
[0104] The PADRE sequence is an amino acid sequence protection sequence that can protect the stability of the vaccine amino acid sequence.
[0105] The 6xHis sequence is a screening tag required for protein expression in the later stage.
[0106] The recombinant multivalent epitope vaccine (IgV_CTLA-4 & Multi-epitope vaccine) designed in this experiment based on IgV_CTLA-4 protein and B. melitensi strain was named V_C4MEV for the first time. The vaccine protein without IgV_CTLA-4 sequence was named MEV.
[0107] Schematic diagram of vaccine protein construction Figure 4 As shown, the amino acid sequence of the finally constructed V_C4MEV is (SEQ ID NO: 63):
[0108] HVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSITGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVI EAAAK PADRE EAAAK SASIAPTLAY AAY RLMPGRNNQR AAY ASLYSSGQGR AAY ASLGGQSCK AAY TGGQAVTLSR AAY VLYDANGGTV AAY SAPDLTPGAV AAY SLYSSGQGR AAY TAGIAGSQIK AAY RVGWTAGAGL GPGPG GVGARIVFAPGENIE GPGPG QGWEFKASHNILYLK GP GPG TQGWEFKASHNILYL GPGPGSGDVVLVRALPGVGA GPGPG NLMVTTDQRMYDFDL GPGPG SGDTVVQTTNARIQA GPGPG GDTVVQTTNARIQAL GPGPG SSGDTVVQTTNARIQ GPGPG ETLGRYATQKVGGGG GPGPG TPNGVVIDLDSPGAD GPGPG KTPNGVVIDLDSPGA GPGPG VNGKQLVLYDANGGT GPGPG QLVLYDANGGTVASL GPGPG KFRVGWTAGAGLEAK GPGPG SKFRVGWTAGAGLEA GPGPG ESKFRVGWTAGAGLE GPGPG FRVGWTAGAGLEAKL GPGPG EGSLRARVGYDLNPV GPGPG FEGSLRARVGYDLNP GPGPG LRARVGYDLNPVMPY GPGPG SLRARVGYDLNPVMP KK PSPVNWNYTMQVGTNS KK ERGSTISGEYDANVKQ KK HGTQTDARMASLLRNR KK LGRYATQKVGGGGSNQ KK IATPQTKYGQGYRAGP KK PMPRMETERMEMRANEKKMRMEKDATERMEMRAN KK AGIAGSQIKLNNGLDD KK RVEYRYTQYGNKNYDL KK NGENICPRTEINSRCE KK LLACILITLASPSWA KK KSSGDT VVQ KK HHHHHH.
[0109] (5) According to the connection method of (1)-(4) above, IgV_CTLA-4 (SEQ ID NO: 15) was eliminated to construct the MEV vaccine. The amino acid sequence of the MEV finally constructed was (SEQ ID NO: 64):
[0110] EAAAK PADREEAAAK SASIAPTLAY AAY RLMPGRNNQR AAY ASLYSSGQGR AAY ASLGGQSCK AAY TGGQAVTLSR AAY VLYDANGGTV AAY SAPDLTPGAV AAY SLYSSGQGR AAYT AGIAGSQIK AAY RVGWTAGAGL GPGP G GVGARIVFAPGENIE GPGPG QGWEFKASHNILYLK GPGPG TQGWEFKASHNILYL GPGPG SGDVVLVRALPGVGA GPGPG NLMVTTDQRMYDFDL GPGPG SGDTVVQTTNARIQA GPGPG GDTVVQTTNARIQAL GPGPG SSGDTVVQTTNARIQ GPGPG ETLGRYATQKVGGGG GPGPG TPNGVVIDLDSPGAD GPGPG KTPNGVVIDLDSPGA GPGPG VNGKQLVLYDANGGT GPGPG QLVLYDANGGTVASL GPGPG KFRVGWTAGAGLEAK GPGPG SKFRVGWTAGAGLEA GPGPG ESKFRVGWTAGAGLE GPGPG FRVGWTAGAGLEAKL GPGPG EGSLRARVGYDLNPV GPGPG FEGSLRARVGYDLNP GPGP G LRARVGYDLNPVMPY GPGPG SLRARVGYDLNPVMP KK PSPVNWNYTMQVGTNS KK ERGSTISGEYDANVKQ KK HGTQTDARMASLLRNR KK LGRYATQKVGGGGSNQ KK IATPQTKYGQGYRAGP KKPMPRMETERMEMRANE KK MRMEKDATERMEMRAN KK AGIAGSQIKLNNGLDD KK RVEYRYTQYGNKNYDL KK NGENICPRTEINSRCE KK LLACILITLASPSWA KK KSSGDTVVQ KK HHHHHH.
[0111] The results showed that the V_C4MEV protein was composed of 890 amino acids, with a molecular weight of about 92KD and a molecular formula of C 4026 H 6368 N 1182 O 1233 S 27 The instability index (II) of the vaccine protein is 24.88 (when the instability index is greater than 40, the protein is unstable), which is a stable hydrophilic protein, and its antigenicity is 1.1546 and is not allergenic. In addition, the solubility of the vaccine protein is 0.9984, indicating that the protein antigen is soluble.
[0112] MEV protein is composed of 776 amino acids, with a molecular weight of about 80KD and a molecular formula of C 3489 H 5516 N 1042 O 1066 S 19 The instability index (II) of the MEV protein is 22.97, which is a stable hydrophilic protein, and its antigenicity is 1.2373 and is non-allergenic. In addition, the solubility of the vaccine protein is 0.997, indicating that the protein antigen is soluble.
[0113] 5. Prediction of secondary and tertiary structures of vaccine proteins
[0114] The secondary and tertiary structures of V_C4MEV were predicted using the online software SOMPA and SWISS-MODEL.
[0115] Figure 5 Prediction of the secondary and tertiary structures of V_C4MEV; A: Prediction of the secondary structure of V_C4MEV; B: Prediction of the tertiary structure of V_C4MEV; (C) Hydrogen bonds of V_C4MEV, the “pink area” represents the donor and the “green area” represents the acceptor.
[0116] Figure 6Evaluation of the tertiary structure model of V_C4MEV; A: red represents α-helix, green represents β-turn, cyan represents β-fold, and gray represents random coil; B: Z-score diagram of the tertiary structure of V_C4MEV; C: Ramachandran diagram.
[0117] The results showed that V_C4MEV contained 20.04% α-helix, 8.17% β-turn, 43.78% random coil, and 28% extended chain. Ramachandran plot analysis showed that 93.60% of the protein residue regions were favorable, 4.93% were allowed, and 1.47% were not allowed. The distribution of these structural elements was consistent with the tertiary structure, indicating that the tertiary structure prediction of V_C4MEV was accurate and the tertiary model had a high credibility.
[0118] 6. Molecular Docking
[0119] Taking advantage of the strong affinity between CTLA-4 and B7 molecules, the highly variable region IgV_CTLA-4 of the CTLA-4 molecule is embedded in MEV to enhance the APCs' ability to present vaccine proteins in order to generate stronger specific T cell responses and B cell-mediated immune responses.
[0120] In order to prove that V_C4MEV can have a high binding affinity with B7 molecules, this experiment used molecular docking technology to verify the interaction between V_C4MEV and B7 molecules, and used the software PyMol and Ligplot to draw the interaction interface of the V_C4MEV-B7-1 / V_C4MEV-B7-2 complex ( Figure 7 ). Figure 7 Molecular docking of V_C4MEV molecule with B7. Blue represents V_C4MEV molecule, and green represents B7-1 and B7-2; A: This figure shows the molecular docking complex between V_C4MEV protein and B7-1. In the interaction area, the red dotted line represents the ionic bond, the green dotted line represents the hydrogen bond, and the bond length is represented by the midpoint value; B: This figure shows the molecular docking complex between V_C4MEV protein and B7-2. C4MEV protein and B7-2 dock through intramolecular interactions, which confirms that the vaccine protein is precisely and strongly bound to the B7 molecule expressed on APCs, and the body's immune cells can efficiently take up the vaccine protein and present antigens.
[0121] 7. Immune simulation
[0122] Online immune simulation was performed using the C-ImmSim server, and the vaccination strategy was consistent with the in vivo experiment. The random seed was set to 1000, and the injection time step was set to 1, 42, and 84 (with a 2-week interval between vaccinations). The "AMHC class I" was set to A0201 and A2402, the "B MHC class I" was set to B1301 and B1501, and the "DR MHC class II" was set to DRB1_0701 and DRB1_1501. Other parameters were set to default values.
[0123] Figure 8 The results of immune simulation are shown in Figure 1. A: B cell isotypes in different states; B: immunoglobulins in various states; C: Th cell isotypes in different states; D: TC cell isotypes in different states; E: NK cells in different states; F: DC in various states; G: macrophages in various states; H: states of different Th cell subsets; I: levels of various cytokines. Figure 8 It showed that the levels of corresponding cytokines such as IFN-γ and IL-4 increased within a short period of time after vaccination. At the same time, the antibody reserves of IgGl, IgG2 and IgM also continued to increase with vaccination.
[0124] 8. In vitro experiments
[0125] This experiment included 18 healthy controls (adults aged 18-60 years) from the First Affiliated Hospital of Xinjiang Medical University. Peripheral blood (4 mL / person) was collected from all subjects, and peripheral blood mononuclear cells (PBMCs) were separated and stored for subsequent in vitro experiments.
[0126] Codon optimization and protein expression of MEV protein and V_C4MEV protein were completed by Shanghai Sangon Biotechnology Co., Ltd. ( Figure 9 ).
[0127] After PBMCs were isolated and collected, they were stimulated with PBS buffer (control group, n=6), MEV protein (M group, n=6) and V_C4MEV protein (V group, n=6) for 48 hours in a humidified incubator at 37°C and 5% CO2. Cell culture supernatants were collected.
[0128] CBA was used to detect IFN-γ and IL-4. ELISPOT was used to detect the immunogenicity of specific antibody secreting cells (ASCs). The results of using CBA to detect IL-4 and IFN-γ levels are shown in Figure 2. Figure 10As shown in A. According to the analysis, the average IFN-γ secretion of the control group was 4.55pg / mL, the average IFN-γ secretion of the M group was 91.10pg / mL, and the average IFN-γ secretion of the V group was 129.3pg / mL. In addition, the average IL-4 secretion of the control group was 4.94pg / mL, the average IL-4 secretion of the M group was 55.98pg / mL, and the average IL-4 secretion of the V group was 82.76pg / mL. Two independent sample t tests were used to compare the IFN-γ and IL-4 secretion levels between the control group, M group, and V group. Compared with the control group, the IFN-γ secretion of the M group was significantly higher (t=22.76, P<0.001), and the IFN-γ secretion of the V group was significantly higher than that of the M group (t=3.87, P<0.01) ( Figure 10 A). Similarly, compared with the control group, the IL-4 secretion of group M was significantly increased (t=11.61, P<0.001), and compared with group M, the IL-4 secretion of group V was significantly increased (t=5.43, P<0.001) ( Figure 10 B), thus verifying that group V activated specific immune cells. In in vitro experiments, such as Figure 11 C and Figure 11 D, ELISPOT was used to detect ASCs in peripheral blood mononuclear cells of healthy subjects. After stimulating PBMCs with antigenic proteins, it was found that V_C4MEV activated B cells more than MEV. The average number of immune spots in the M group was 369.8, and the average number of immune spots in the V group was 398.5, with a statistically significant difference (t=2.96, P<0.05).
[0129] 9. In vivo experiments
[0130] In this experiment, an animal in vivo experimental model was established by injecting mice with V_C4MEV vaccine protein. Specifically, 18 8-week-old SPF female BALB / c mice were divided into three groups. Among them, mice in group V were injected with V_C4MEV protein (n=6), mice in group M were injected with MEV protein (n=6), and mice in the control group were injected with the corresponding carrier solvent (n=6). All mice received three immunization injections, with an interval of two weeks between two immunizations. During the first immunization, mice in groups M and V were subcutaneously injected with 0.5 ml of an emulsion containing 50 μg of complete Freund's adjuvant (CFA) and antigen recombinant protein. During the second and last immunizations, CFA was replaced with incomplete Freund's adjuvant (IFA). The control group was injected with CFA and IFA only. Mouse spleen cells were collected 10 days after the last immunization, and single cell suspensions were prepared under sterile conditions. Each group consisted of 6 samples, and the spleen cells in each group were stimulated by M protein for 24 hours or 72 hours.
[0131] After three inoculations, ELISA was used to detect IFN-γ and IL-4 in the culture supernatant of mouse spleen cells, and FCM was used to detect CD4 + T cells and CD8 + T cell production status;
[0132] Figure 11 Results of in vivo experiments; A: Flowchart illustrating the mouse vaccination strategy. Different groups of mice were injected with "adjuvant", "adjuvant + M protein" or "adjuvant + V_C4MEV protein"; B: CD4 + T cells and CD8 + Flow gating strategy for T cells; C: Statistical analysis in the graphs used two independent sample t-tests (*P < 0.05, **P < 0.01, ***P < 0.001) to compare CD4 + T cells and CD8 + The percentage of T cells; D: shows the statistical evaluation of the IFN-γ and IL-4 concentration levels in the control group, M group, and V group. Statistical analysis was performed using two independent sample t tests (**P < 0.01, ***P < 0.001); E: This figure shows the statistical analysis of the total IgG concentration levels in the control group, M group, and V group. The statistical method was two independent sample t tests (***P < 0.001).
[0133] Figure 11 A shows a schematic diagram of the mouse vaccination strategy. FCM was used to confirm specific CD4 + T cells and CD8 + The level of T cells ( Figure 11 B) The results showed that the specific CD4 + There was a significant difference in T cell levels between the M and V groups (P < 0.001). + There were significant differences in the levels of T cells (P < 0.001). In addition, there were significant differences in the levels of specific CD8 + There were significant differences in the levels of T cells ( Figure 11 C).
[0134] ELISA was used to detect the levels of IFN-γ and IL-4 in the supernatant of spleen cell culture. The IFN-γ concentration in the control group was 59.33 pg / mL, that in the M group was 457.65 pg / mL, and that in the V group was 595.40 pg / mL ( Figure 11D). The IFN-γ concentration level in the M group was significantly higher than that in the control group (t=29.69, P<0.001), and the IFN-γ concentration level in the V group was significantly higher than that in the M group (t=5.85, P<0.001). The IL-4 concentration in the control group was 28.57 pg / mL, in the M group was 141.94 pg / mL, and in the V group was 176.56 pg / mL ( Figure 11 D). The IL-4 concentration level in the M group was significantly higher than that in the control group (t=22.12, P<0.001), and the IL-4 concentration level in the V group was significantly higher than that in the M group (t=3.85, P<0.01).
[0135] ELISA was used to detect IgG levels to reflect the activation of B cells. In the ELISA experiment, the total IgG concentration in the control group was 45.83μg / mL, in the M group was 74.44μg / mL, and in the V group was 105.6μg / mL. The total IgG concentration in the M group was significantly higher than that in the control group (t=10.53, P<0.01), and the total IgG concentration in the V group was significantly higher than that in the M group (t=9.65, P<0.01) ( Figure 11 E).
[0136] In summary, this experiment confirmed that V_C4MEV can activate specific cellular immunity in mice; ELISA technology was used to detect the production of specific antibodies in the supernatant, thus verifying that V_C4MEV has strong antigenicity.
[0137] The preferred specific embodiments of the present invention are described in detail above. It should be understood that a person skilled in the art can make many modifications and changes based on the concept of the present invention without creative work. Therefore, any technical solution that can be obtained by a person skilled in the art through logical analysis, reasoning or limited experiments based on the concept of the present invention on the basis of the prior art should be within the scope of protection determined by the claims.
Claims
1. A Brucella recombinant multivalent epitope vaccine, characterized in that: Including IgV_CTLA-4, linked CD8 + T cell epitopes, ligated CD4 + T cell epitopes, ligated linear B cell epitopes, and ligated conformational B cell epitopes; The amino acid sequence of IgV_CTLA-4 protein is SEQ ID NO: 15; CD8 after connection + The amino acid sequence of the T cell epitope is: SEQ ID NO: 59; CD4 after connection + The amino acid sequence of the T cell epitope is SEQ ID NO: 60; The amino acid sequence of the linear B cell epitope after ligation is SEQ ID NO: 61; The amino acid sequence of the ligated conformational B cell epitope is SEQ ID NO:
62.
2. The Brucella recombinant multivalent epitope vaccine according to claim 1, characterized in that Also included are the PADRE sequence and the 6xHis sequence.
3. The Brucella recombinant multivalent epitope vaccine according to claim 2, characterized in that Also includes Linker-EAAK, Linker-AAY, Linker-GPGPG and Linker-KK.
4. The Brucella recombinant multivalent epitope vaccine according to claim 3, characterized in that The amino acid sequence of the recombinant multivalent epitope vaccine is SEQ ID NO:
63.
5. A method for preparing the recombinant multivalent epitope vaccine according to claim 4, characterized in that: The following steps are involved: Step 1: CD8 + T cell epitopes were connected by Linker-AAY to obtain linked CD8 + T cell epitope, amino acid sequence: SEQ ID NO: 59; CD4 + T cell epitopes were connected by Linker-GPGPG to obtain linked CD4 + T cell epitope, the amino acid sequence is: SEQ ID NO: 60; the linear B cell epitope is connected by Linker-KK to obtain a connected linear B cell epitope, the amino acid sequence is: SEQ ID NO: 61; the conformational B cell epitope is connected by Linker-KK to obtain a connected conformational B cell epitope, the amino acid sequence is: SEQ ID NO: 62; In the second step, IgV_CTLA-4, PADRE sequence, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62 and 6xHis sequence were connected in order. The amino acid sequence of IgV_CTLA-4 is SEQ ID NO:15; SEQ ID NO:15, PADRE sequence and SEQ ID NO:59 were connected in sequence through Linker-EAAK; SEQ ID NO:59 and SEQID NO:60 were connected through Linker-GPGPG; SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62 and 6xHis sequence were connected through Linker-KK to obtain the recombinant multivalent epitope vaccine V_C4MEV with an amino acid sequence of SEQ ID NO:
63.
6. Use of the recombinant multivalent epitope vaccine according to claim 1 or 4 in stimulating the body to resist Brucella.
7. A vector of nucleic acid of the recombinant multivalent epitope vaccine according to claim 1 or 4.
8. Use of the recombinant multivalent epitope vaccine according to claim 1 or 4 in the preparation of drugs for preventing and treating brucellosis.
Citation Information
Cited By
Detection method of CTLA-4 gene insertion / deletion marker of down producing goat and application of detection method
CN116287315A
A method for detecting insertion / deletion markers of the CTLA-4 gene in cashmere goats and its application
CN116287315B
Brucella recombinant multi-epitope vaccine and application thereof
CN121930369A
Brucella recombinant polyepitope vaccine and application thereof
CN121930369B
